Project structure

The DiscoGnosis consortium takes into consideration the requirements for a point-of-care diagnostic platform as well as the requirements set by the special, inherent conditions met at the areas/countries of need, and has organized the project workload in the following 9 Work Packages (WPs):

WP#  

WP Title

Type of
activity *

Leading partner

WP Leader

WP1

Project ManagementWP1: Project management (ALU-FR / IMTEK)

This WP is occupied with the administrative and financial coordination and management of DiscoGnosis. The main management bodies are identified: (i) Project Coordinator (PC); (ii) the Management & Scientific Committee (MSC); (iii) the Work Package Leaders (WPL); (iv) the IPR manager. In addition, intra-consortium thematic teams are setup for the faster and more efficient communication and cooperation.

MGT

ALU-FR/ IMTEK

Konstantinos Mitsakakis

WP2

System specifications and quality controlWP2: System specifications and quality control (MAST)

This WP aims at setting the roadmap of the project with a set of documents, which will be reviewed and updated throughout the project. This set of documents includes: (i) the specifications of the disposable, its components, the reader, and interfaces between them; (ii) a risk management assessment, where the identified project risks will be listed together with their probability, impact and actions for their mitigation/backup; (iii) a quality control roadmap, which will summarize the processes that require quality control, the parameters that will characterize them as well as the tools/mechanisms for quality control assessment.

RTD

MAST

Liz Gillies

WP3

Multiplexed detectionWP3: Multiplexed detection (MMD)

This WP describes the activities that will be carried out in order to achieve multiplexed detection on the disc platform. These activities will focus on three technological directions: (i) development of an array of magnetic beads and quantum dots for advanced multiplexing; (ii) development of special microfluidic units for facilitating the multiplexing components; (iii) upgrading a dedicated optics detection system.

RTD

MMD

Sven Goethel

WP4

DNA assay developmentWP4: DNA assay development (UMG)

This WP is dedicated on the development of nucleic acid-based assays from nucleic acid extraction and purification to amplification and real-time detection. The amplification will take place with isother-mal technology, which is beneficial for energy and time saving. Various options for multiplexing will be investigated.

RTD

UMG

Frank Hufert

WP5

Protein assay developmentWP5: Protein assay development (UHBS)

This WP is dedicated on the development of protein-based assays in order to detect the marker that is representative of the probed diseases. Based on the targeted disease, either antigens and/or antibodies will be the analytes of interest. Various options for multiplexing will be investigated.

RTD

UHBS

Georgette Beugelaar

WP6

Microfluidic platform, components and system integrationWP6: Microfluidic platform, components and system integration (ALU-FR / IMTEK)

This WP focuses on the development of proper fluidic unit operations on the disc in order to perform the various sample preparation and analysis steps of the raw sample (blood) till the detection step(s). It also involves the development of a patient-to-platform interface in the form of a Blood Transfer Device (BTD). Together with reagent pre-storage on the disc, this WP aims at a fully automated microfluidic platform.

RTD

ALU-FR/ IMTEK

Konstantinos Mitsakakis

WP7

Disposable production technologyWP7: Disposable production technology (Rohrer)

In this WP, the existing blister packaging production technology based on (micro)thermoforming will be used as basis to develop a production technology for microfluidic disposables. This includes development of new tools and evaluation of flexibility in manufacturing. The following production processes will be addressed: (i) thermoforming; (ii) surface treatment/functionalization of the foil (optional/only when necessary); (iii) reagent dispensing; (iv) sealing; (v) cutting.

RTD

Rohrer

Andreas Blömeke

WP8

Clinical validation and data managementWP8: Clinical validation and data management (UHBS)

This WP is focused on translation to an African context and on clinical validation of the DiscoGnosis platform, eventually at the point-of-need. The main targets of the WP will be to: (i) prepare the infrastructure for device/test evaluation and validation in sub-Saharan Africa; (ii) perform field trials to assess feasibility, robustness, sensitivity, specificity and clinical value for patients; (iii) establish an internet-based management system of the data derived from patients’ diagnosis profiling; (iv) establish Quality Control parameters and tools for the system validation; (v) training of end-user personnel at remote areas of African rural hospitals, where the final prototype will be used.

RTD

UHBS

Patrick Hunziker

WP9

Dissemination and Exploitation WP9: Dissemination and Exploitation (CLINAM)

This WP focuses on setting up the proper dissemination tools and the strategy in order to familiarize the research community as well as the public with the aims and achievements of DiscoGnosis. The dissemination is organized on three levels, namely event-based (e.g., workshops), web-based (e.g., dedicated website), and publication-based (e.g., peer-reviewed journals). In terms of exploitation, the WP describes the measures taken to investigate future opportunities for exploitation of the project results, a business case and basic market analysis for final prototype commercialization.

MGT

CLINAM

Beat Löffler

* MGT: Management activity
*
RTD: Research & Technological Development activity

 

The strong interdependence between the WPs is depicted in the following Figure. The consortium has composed internal 2- or 3-member thematic groups for a more rapid acting and decision making.

Interdependency and cooperation between WPs in DiscoGnosis